[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 2 sources · 9 days · First seen · Last updated

Atopic dermatitis monoclonal antibody clinical developments

Overview

Clinical data released in October 2026 highlights long-term efficacy for monoclonal antibody treatments targeting atopic dermatitis and prurigo nodularis.

Initial findings from the ARCADIA and OLYMPIA studies showed that nemolizumab, which inhibits interleukin-31 (IL-31) signaling, maintained skin clearance and itch relief for up to three years. In the ARCADIA study, 80% of early responders achieved an EASI-90 score by week 152, while the OLYMPIA study reported that over 85% of patients with prurigo nodularis experienced clinically meaningful itch improvement.

Subsequent reports expanded on these advancements, including Phase 2 data showing nemolizumab provided lasting improvements in itch, sleep, and quality of life for children aged 2 to 11. Additionally, 5-year data for lebrikizumab was presented, demonstrating sustained skin clearance and itch control in adults and adolescents, with 92.9% of subjects achieving EASI-75 at the 108-week mark.

Entities

Nemolizumab · Galderma · atopic dermatitis · University of California San Francisco · lebrikizumab

Timeline

  1. [HEALTH] 2 sources
    Atopic dermatitis treatments show long-term efficacy in new clinical data

    Clinical studies show promising long-term results for nemolizumab in children and lebrikizumab in adults treating moderate-to-severe atopic dermatitis.

  2. [HEALTH] 2 sources
    Nemolizumab shows sustained skin and itch relief for up to 3 years

    Long-term data shows nemolizumab provides sustained skin clearance and itch relief for up to three years in patients with atopic dermatitis and prurigo nodularis.

Sources

consultantlive.com · mdmag.com